朊粒蛋白PrP~(Sc)寡聚体的形成与跨膜毒性

朊粒蛋白(prionprotein,PrP)传染致病机制一直是朊粒(prion)研究领域的焦点.由正常型朊粒蛋白(PrPC)向致病型朊粒蛋白(PrPSc)的转变是致病的关键步骤.本文综述了近年来PrPC向PrPSc转变的结构变化特征、PrPSc由单体形成寡聚体的组装机制、以及PrPSc寡聚体的跨膜机制与细胞毒性间的关系等方面的研究进展.     

Tau融合蛋白及其缺失突变体与朊蛋白的体外作用分析

在部分朊病毒病（prion diseases）中,高度磷酸化的微管相关蛋白tau与朊蛋白(prion protein,PrP)发生共定位,tau蛋白可能在朊病毒病的病理机制中有重要作用. 本室已经证明二者可以发生分子间相互作用,本文进一步分析了tau蛋白与prion的体外相互作用及作用位点. 利用RT-PCR方法从人源细胞系SHSY5Y cDNA中扩增出微管相关蛋白tau全长cDNA序列,克隆至质粒pGEX-2T载体,在大肠杆菌中诱导表达融合蛋白GST-tau. 利用GST pull-down及免疫共沉淀方法检测全长tau蛋白与PrP23-231的分子间相互作用. 进一步表达tau 蛋白的各种缺失突变体,确定tau蛋白与PrP蛋白的相互作用位点. 结果表明,所表达的全长tau蛋白及各种缺失突变体均为可溶性蛋白,Western印迹结果显示,各种蛋白均能很好的被tau蛋白单抗识别. GST pull-down和免疫共沉淀实验均显示,原核表达的全长tau蛋白可与全长的PrP蛋白在体外发生相互作用,并确定相互作用位点位于tau蛋白的N端序列及中段的重复区. 上述结果为研究tau蛋白与PrP的相互作用在朊病毒病的发病机制中的意义提供了一定的理论基础.     

抗牛PrP多肽单克隆抗体的制备及其在牛PrP 检测中的应用

为获得广谱抗哺乳类动物PrP单克隆抗体(monoclonal antibody, McAb), 用牛朊蛋白(prion protein, PrP)多肽(209~228 aa)与匙孔槭血蓝蛋白(keyhole limpet hemocyanin, KLH)偶联物免疫Balb/C小鼠. 经细胞融合和克隆后获得针对上述多肽的杂交瘤细胞株. 分别用Western blot和免疫组化(immunohistochemistry, IHC)的方法检测这些McAbs与重组人(human, Hu)、牛(bovine, Bo)、仓鼠(hamster, Ha)PrP蛋白、牛脑组织中的正常朊蛋白(cellular PrP, PrPc)和致病性朊蛋白(scrapie of prion, PrPSc)的反应性. 本文为制备高效价抗PrP McAb提供了一个简单、易行的方法. 制备的抗体可用于研究哺乳类PrP生物学特性, 检测可传播性海绵样脑病, 特别是对牛海绵样脑病的诊断具有重要意义.     

全长朊粒蛋白淀粉样纤维引发细胞毒性的机制研究

目的 朊病毒病(prion disease)是一类由朊粒蛋白(PrP)发生错误折叠、聚集形成致病性的PrP^Sc导致的具有高致死率的神经退行性疾病。本文在细胞和动物水平开展了PrP纤维诱导内源PrP聚集和毒性机制的研究。方法 通过超速离心结合蛋白质免疫印迹实验检测PrP聚集；通过氧化压力实验，使用Annexin V-FITC/PI双染检测细胞凋亡；运用细胞超薄切片技术检测细胞线粒体形态；在动物水平，分离新生小鼠的前额叶，进行横断切片培养，在脑片上接种PrP纤维。结果 PrP纤维种子可以诱导内源PrP聚集，PrP纤维可以诱导细胞内氧化压力升高和细胞凋亡，PrP纤维可以引起线粒体损伤，PrP纤维可以诱导小鼠前额叶内源PrP聚集。结论 本文在细胞和动物水平证实体外组装的PrP淀粉样纤维具有细胞毒性和潜在的感染性。     

Doppel蛋白及其对动物生殖的影响

Doppel(简称Dpl)是新发现的一种糖基磷脂酰肌醇锚定(GPI)结构糖蛋白, 在结构上与朊蛋白(Prion protein, PrP)相似, 其编码基因位于朊蛋白编码基因(Prion protein gene, PRNP)下游, 但在生理功能上两者差异较大。Dpl蛋白在成年动物体内的表达主要集中在睾丸组织, 对雄性动物精子完整性、活力以及维持正常受精能力等生殖功能具有重要作用。以下主要综述了Dpl蛋白的生物学特征、生理功能以及对雄性动物生殖调控的影响, 旨在为Dpl蛋白的功能研究和雄性动物生殖调控研究提供理论参考。     

线粒体靶向抗氧化剂Mitoquinone和积雪草酸对朊病毒感染的神经细胞的治疗作用研究

朊病毒病(Prion diseases)是一类具有致死性、传染性和进行性的神经退行性疾病。研究发现朊病毒感染的细胞和动物模型中均存在着线粒体功能异常和氧化应激,这很有可能在朊病毒病发生发展中起重要作用。为探究线粒体靶向抗氧化剂对朊病毒感染是否具有一定的治疗作用,我们选出两种线粒体靶向抗氧化剂,以一定浓度作用于朊病毒感染神经细胞系,并观察细胞活性和线粒体功能的变化情况。结果显示,Mitoquinone(MitoQ)和积雪草酸(Asiatic acid,AA)这两种药物能够显著提高朊病毒感染细胞的活性,降低其活性氧(Reactive oxygen species,ROS)水平,上调ATP5β的表达水平,提示这两种药物对朊病毒感染细胞有一定的治疗作用,本研究为朊病毒病发病机制以及治疗的研究提供了新的思路。     

朊病毒病相关细胞凋亡

朊病毒病是一组蛋白质折叠异常的蛋白质构象病,由正常朊蛋白PrP^C转化为具蛋白酶抗性的异常朊蛋白PrP^Sc并在中枢神经系统聚集引起.其主要的病理变化为神经元的丢失,脑组织的海绵样变及神经胶质细胞增生.目前认为其神经元丢失的主要原因为凋亡及自噬等,而神经元的凋亡涉及多种因素及途径,机制较为复杂.对神经元凋亡的研究将有助于揭示朊病毒病的发病机制.     

朊蛋白相关蛋白Shadoo与朊病毒病

朊病毒病,即传染性海绵状脑病（transmissible spongiform encephalopathies, TSEs）,是一类传染性、致死性神经退行性疾病。在朊病毒病的病理过程中,细胞正常朊蛋白PrP。转化为异常构象的PrP是至关重要的,但是PrP‘的正常生理功能仍不清楚。国外学者利用比较基因组学发现了-个新的朊蛋白相关蛋白-shadoo（Sho）。Sho与PrP。在氨基酸序列和细胞定位的相似性及主要在脑组织表达,使它成为-个非常值得研究的PrP相关蛋白。对Sho可能存在的与PrP。重叠的功能甚至直接相互作用的研究工作,将对今后揭示PrPc正常生理功能以及揭示Pfion病发病机制具有重要现实意义。     

朊蛋白研究进展

朊蛋白（prion protein,OPrp^c）是一个非传统的感染原,尚未发现含核酸,可引起人和动物的传染性脑退化病。PrP^c是一个正常的蛋白,主要分布于神经元表面,属于肌醇磷脂锚蛋白类。由PrPc向PrP^sc转变即产生疾病。本综述简单介绍了朊蛋白结构、功能及发病机理,并提出了目前尚待研究的问题。     

羊瘙痒因子263K感染仓鼠临床终末期脑中αB-晶体蛋白表达的研究

αB-晶体蛋白(αB-crystallin)是小热休克蛋白(Small heat shock protein,sHSP)家族的代表成员,已发现与多种神经退行性疾病发生发展密切相关,但至今为止对αB-晶体蛋白在朊病毒病发生发展中可能扮演的角色研究甚少,作用尚不清楚。本研究利用羊瘙痒因子仓鼠敏感株263K感染仓鼠建立的朊病毒实验动物模型,通过免疫印迹(Western blots)和免疫组织化学染色观察到伴随PrPSc在感染终末期动物脑组织中大量沉积,αB-晶体蛋白表达显著上调,比正常对照增高3倍。免疫荧光双染确定其分布的主要细胞类型为星形胶质细胞,神经元中未检测到表达。感染动物中高表达的αB-晶体蛋白与异常沉积的PrPSc无明显共定位。此研究为进一步探讨和揭示αB-晶体蛋白在朊病毒病中可能的作用和分子机制奠定了基础。     

Prion diseases: contribution of high-resolution immunomorphology

The transmisible spongiform encephalopathies or prion diseases are fatal neurological diseases that occur in animals and humans. They are characterized by the accumulation in the cerebral tissue of the abnormal form of prion protein (PrP^sc) produced by a post-translational event involving conformational change of its normal cellular counterpart (PrP^c). In this short review, we present some results on the biology of prion proteins which have benefited from morphological approaches combining the electron microscopy techniques and the immunodetection methods. We discuss data concerning in particular the physiological function of the normal cellular prion prion (PrP^c) which have allowed to open up new vistas on prion diseases, the biogenesis of amyloid plaque and the cellular site involved in the prion protein conversion process.     

Prion diseases: dynamics of the infection and properties of the bistable transition

Prion diseases are thought to result from a pathogenic, conformational change in a cellular protein, the prion protein. The pathogenic isoform seems to convert the normal isoform in an autocatalytic process. In contrast to the conditions used for in vitro studies of enzyme kinetics, the concentration of the catalyst is not much lower than that of the substrate in the course of infection. This feature may endow the system with a time-hierarchy allowing the pathogenic isoform to relax very slowly in the course of infection. This may contribute to the long incubation periods observed in prion diseases. The dynamic process of prion propagation, including turnover of the cellular prion protein, displays bistable properties. Sporadic prion diseases may result from a change in one of the parameters associated with metabolism of the prion protein. The bistable transition observed in sporadic disease is reversible, whereas that observed in cases of exogenous contamination is irreversible. This model is consistent with the occurrence of rare, sporadic forms of prion diseases. It may also explain why only some individuals of a cohort develop a prion disease following transient food contamination.     

Potential approaches for heterologous prion protein treatment of prion diseases

Prion diseases, or transmissible spongiform encephalopathies (TSEs) are progressive, fatal neurodegenerative diseases with no effective treatment. The pathology of these diseases involves the conversion of a protease sensitive form of the cellular prion protein (PrP^C) into a protease resistant infectious form (PrP^res). The efficiency of this conversion is predicated upon a number of factors, most notably a strong homology between cellular PrP^C and PrP^res. In our recently published study, we infected mice with the RML-Chandler strain of scrapie and treated them with heterologous hamster prion proteins. This treatment was seen to reduce clinical signs of prion disease, to delay the onset of clinical symptoms and to prolong survival. In this current article we discuss potential mechanisms of action of treatment with heterologous prion proteins. We also discuss potential extensions of these studies using a heterologous rabbit PrP-based treatment strategy or a peptide based strategy, and improvement of treatment delivery including a lentiviral-based system.     

Cellular phenotyping of secretory and nuclear prion proteins associated with inherited prion diseases.

The pathogenic mechanisms leading from mutations in the prion protein (PrP) gene to infectious disease are not understood. To investigate the possibility that cellular processing of mutant prion protein may contribute to the formation of infectious particles, a mouse PrP model system has been established using the green fluorescent protein. Three novel PrP mutants were examined employing this model system and compared with wild type as well as known mutant PrPs. Two Creutzfeldt-Jakob disease-associated PrP mutants, PrP T188K and PrP T188R, revealed a secretory pathway to the cell membrane and PrP(Sc)-like properties, i.e. enhanced proteinase K resistance and detergent insolubility similar to other mutant PrPs associated with familial prion diseases. Moreover, a recently described disease-related truncated PrP mutant, PrP Q160(Stop), showed an almost exclusive localization in the nucleus and a catabolism along the proteasomal pathway. Therefore, various distinct pathological mechanisms may cause prion diseases, and aberrant cellular processing may be included in the pathogenesis of prion diseases.     

Therapy for prion diseases: Insights from the use of RNA interference

Insights into the molecular basis and the temporal evolution of neurotoxicity in prion disease are increasing, and recent work in mice leads to new avenues for targeting treatment of these disorders. Using lentivirally mediated RNA interference (RNAi) against native prion protein (PrP), White et al report the first therapeutic intervention that results in neuronal rescue, prevents symptoms and increases survival in mice with established prion disease.1 Both the target, and the timing, of treatment here are crucial to the effectiveness of this strategy: the formation of the neurotoxic prion agent is prevented at a point when diseased neurons can still be saved from death. But the data also give new insights into the timing of treatment in the context of the pattern of spread of prion infection throughout the brain, with implications for developing the most effective treatments.

This perspective considers developments in the field that led to the rationale for targeting endogenous prion protein (PrP) in prion therapeutics and to the discovery of a window of reversibility of early neuronal damage in prion disease. It introduces RNA interference (RNAi) and its therapeutic use in this context and discusses insights into prion pathogenesis and future treatment strategies and goals. A key concept is targeting the critical brain regions for the spread of prion replication. This may have relevance in other neurodegenerative diseases due to protein misfolding, which recent literature suggests may also propagate throughout the brain in disease-specific patterns.     

Therapy for prion diseases: Insights from the use of RNA interference

Insights into the molecular basis and the temporal evolution of neurotoxicity in prion disease are increasing, and recent work in mice leads to new avenues for targeting treatment of these disorders. Using lentivirally mediated RNA interference (RNAi) against native prion protein (PrP), White et al. report the first therapeutic intervention that results in neuronal rescue, prevents symptoms and increases survival in mice with established prion disease.¹ Both the target and the timing of treatment here are crucial to the effectiveness of this strategy: the formation of the neurotoxic prion agent is prevented at a point when diseased neurons can still be saved from death. But the data also give new insights into the timing of treatment in the context of the pattern of spread of prion infection throughout the brain, with implications for developing the most effective treatments.Key words: prion, RNA interference, gene therapy, neurodegeneration, synapticThis perspective considers developments in the field that led to the rationale for targeting endogenous prion protein (PrP) in prion therapeutics and to the discovery of a window of reversibility of early neuronal damage in prion disease. It introduces RNA interference (RNAi) and its therapeutic use in this context and discusses insights into prion pathogenesis and future treatment strategies and goals. A key concept is targeting the critical brain regions for the spread of prion replication. This may have relevance in other neurodegenerative diseases due to protein misfolding, which recent literature suggests may also propagate throughout the brain in disease-specific patterns.     

Natural and experimental prion diseases of humans and animals.

Prions cause transmissible and genetic neurodegenerative diseases. Infectious prion particles are composed largely, if not entirely, of an abnormal isoform of the prion protein (PrPSc), which is encoded by a chromosomal gene. Although the PrP gene is single copy, transgenic mice with both alleles of the PrP gene ablated develop normally. A post-translational process, as yet unidentified, converts the cellular prion protein (PrPC) into PrPSc. Scrapie incubation times, neuropathology and prion synthesis in transgenic mice are controlled by the PrP gene. Mutations in this gene are genetically linked to the development of neurodegeneration. Transgenic mice expressing mutant PrP spontaneously develop neurological dysfunction and spongiform neuropathology. Future investigations of prion diseases using molecular biological and genetic approaches promise to yield much new information about these once enigmatic disorders.     

Molecular advances in understanding inherited prion diseases

The prion diseases are neurodegenerative disorders that have attracted great interest because of the possible link between bovine spongiform encephalopathy (BSE) and variant Creutzfeldt-Jakob disease (CTD) in humans. Possible transmission of these diseases has been linked to a single protein termed the prion protein. This protein is an abnormal isoform of a normal synaptic glycoprotein. The majority of prion diseases does not appear to be caused by transmission of an infectious agent but occur spontaneously with no known cause. The strongest supporting evidence that the prion protein is the causative agent in prion disease comes from specific inheritable forms of prion disease which are linked to single point mutations in the prion protein gene. Paradoxically, these point mutations, although autosomal dominant with 100% penetrance do not lead to disease until late in life. Molecular techniques are now being used extensively to determine how these point-mutations alter the prion protein’s normal structure and activity. This review deals with the latest insights into how inherited mutations in the prion protein gene lead to neurodegenerative disease.     

Selective oxidation of methionine residues in prion proteins.

Prion proteins are central to the pathogenesis of several neurodegenerative diseases through the postulated conversion of the endogenous cellular isoform (PrPc) into a pathogenic isoform (PrPSc). Although the cellular function of normal prion protein remains unresolved a number of studies have shown that prion proteins may be involved in the cellular response to oxidative stress. Here, using purified recombinant sources of mouse and chicken PrP refolded in the presence of copper (II) we show that the methionine residues of the protein are uniquely susceptible to oxidation. We suggest that Met residues may form an essential part of the mechanism of the antioxidant activity exhibited by normal prion protein.     

Nanoimaging for prion related diseases

Misfolding and aggregation of prion proteins is linked to a number of neurodegenerative disorders such as Creutzfeldt-Jacob disease (CJD) and its variants: Kuru, Gerstmann-Straussler-Scheinker syndrome and fatal familial insomnia. In prion diseases, infectious particles are proteins that propagate by transmitting a misfolded state of a protein, leading to the formation of aggregates and ultimately to neurodegeneration. Prion phenomenon is not restricted to humans. There are a number of prion-related diseases in a variety of mammals, including bovine spongiform encephalopathy (BSE, also known as “mad cow disease”) in cattle. All known prion diseases, collectively called transmissible spongiform encephalopathies (TSEs), are untreatable and fatal. Prion proteins were also found in some fungi where they are responsible for heritable traits. Prion proteins in fungi are easily accessible and provide a powerful model for understanding the general principles of prion phenomenon and molecular mechanisms of mammalian prion diseases. Presently, several fundamental questions related to prions remain unanswered. For example, it is not clear how prions cause the disease. Other unknowns include the nature and structure of infectious agent and how prions replicate. Generally, the phenomenon of misfolding of the prion protein into infectious conformations that have the ability to propagate their properties via aggregation is of significant interest. Despite the crucial importance of misfolding and aggregation, very little is currently known about the molecular mechanisms of these processes. While there is an apparent critical need to study molecular mechanisms underlying misfolding and aggregation, the detailed characterization of these single molecule processes is hindered by the limitation of conventional methods. Although some issues remain unresolved, much progress has been recently made primarily due to the application of nanoimaging tools. The use of nanoimaging methods shows great promise for understanding the molecular mechanisms of prion phenomenon, possibly leading toward early diagnosis and effective treatment of these devastating diseases. This review article summarizes recent reports which advanced our understanding of the prion phenomenon through the use of nanoimaging methods.Key words: protein misfolding, prion, atomic force microscopy, nanomedicine, force spectroscopy